{
    "abstract": "Carbapenem-resistant Enterobacterales (CRE) are difficult to treat and can cause significant morbidity and mortality, however most data reflect carbapenemase-producing infections.\nOur objective was to evaluate clinical outcomes of non-carbapenemase-producing CRE (nCP-CRE) compared with carbapenem-susceptible Enterobacterales (CSE) infections.\nThis was a retrospective, multicenter, observational study (January 1, 2018 to December 31, 2020). The primary outcome was clinical success at 30 days with secondary outcomes, including clinical success at 90 days, clinical success based on treatment for nCP-CRE, persistent bacteremia, intensive care unit (ICU) admission, length of stay, and rate of \nThe final analysis included 211 patients: 142 (67%) with CSE and 69 (33%) with nCP-CRE infections. Prior carbapenem exposure was more common with nCP-CRE (15% vs 4%, \nOur study found no difference in clinical outcomes between nCP-CRE and CSE infections. Application of this study with future studies would help in determining optimal regimens for these infections.",
    "authors": [
        {
            "affiliation": "Department of Pharmacy, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.",
            "firstname": "Ashita",
            "initials": "A",
            "lastname": "Debnath"
        },
        {
            "affiliation": "Department of Pharmacy, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.",
            "firstname": "Kelly E",
            "initials": "KE",
            "lastname": "Pillinger"
        },
        {
            "affiliation": "Department of Pharmacy, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.",
            "firstname": "Alysa J",
            "initials": "AJ",
            "lastname": "Martin"
        },
        {
            "affiliation": "Division of Infectious Diseases, University of Rochester Medical Center, Rochester, NY, USA.",
            "firstname": "David",
            "initials": "D",
            "lastname": "Dobrzynski"
        },
        {
            "affiliation": "Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.",
            "firstname": "Andrew",
            "initials": "A",
            "lastname": "Cameron"
        },
        {
            "affiliation": "Department of Pharmacy, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.",
            "firstname": "Stephanie",
            "initials": "S",
            "lastname": "Shulder"
        }
    ],
    "conclusions": null,
    "copyrights": null,
    "doi": "10.1177/10600280221132019",
    "journal": "The Annals of pharmacotherapy",
    "keywords": [
        "antibiotics",
        "carbapenem-resistant enterobacteriaceae",
        "carbapenems",
        "clinical practice",
        "drug resistance",
        "enterobacteriaceae infections",
        "infectious diseases",
        "multiple",
        "outcomes"
    ],
    "methods": null,
    "publication_date": "2022-10-22",
    "pubmed_id": "36268974",
    "results": "The final analysis included 211 patients: 142 (67%) with CSE and 69 (33%) with nCP-CRE infections. Prior carbapenem exposure was more common with nCP-CRE (15% vs 4%, ",
    "title": "Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections.",
    "xml": "<Element 'PubmedArticle' at 0x788502e60270>"
}